The initiative will offer young startups between $250,000 and $2 million in seed funding to solve existing problems with issues including renewable energy generation, sustainable architecture and water treatment.
This Series A will be used to fuel the Boston company’s mission of developing drugs that are fully designed, synthesized and tested by artificial intelligence.
